Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C5731006 Disitamab Vedotin in HER2 Expressing Advanced Breast Cancer
2025-521003-52-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in breast cancer, sponsored by Pfizer. Primary endpoint: Objective response. Planned start Dec 2025; status: authorised.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521003-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521003-52-00.